Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin superfamily DCC subclass member 4 (IGDCC4) is a cell surface protein predicted to be involved in cell-cell adhesion and is mainly located at the plasma membrane. It is a member of the immunoglobulin superfamily and contains fibronectin type III domains. IGDCC4 has been implicated in both normal developmental processes and various cancers, with epigenetic changes at its locus associated with birth weight, early childhood adiposity, and tumor progression, particularly in lung adenocarcinoma and breast cancer. Increased methylation or decreased expression of IGDCC4 is linked to more advanced disease states, suggesting its utility as an epigenetic biomarker for cancer prognosis and metabolic disease risk. However, there are currently no known drugs that directly target IGDCC4, nor is it broadly recognized as a therapeutic drug target[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin superfamily DCC subclass member 4 (IGDCC4).